What are the considerations and potential risks for using Ipamorelin (growth hormone secretagogue) in women, particularly those with a history of cancer, diabetes, or other underlying medical conditions? Frontiers Evaluating the toxicity profile of combination immune checkpoint inhibitors: a disproportionality analysis of real world adverse events from the FDA Adverse Event Reporting System for tremelimumab, durvalumab, ipilimumab, and nivolumab Medication Attributable Adverse Events in Heart Failure Trials ScienceDirect Adverse Event Reporting Medical School Office of Research Adverse Event Reporting in Clinical Trials